|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5260300A
(en)
|
1992-11-19 |
1993-11-09 |
American Home Products Corporation |
Rapamycin carbonate esters as immuno-suppressant agents
|
|
WO1994025072A1
(en)
|
1993-04-23 |
1994-11-10 |
American Home Products Corporation |
Rapamycin conjugates and antibodies
|
|
WO1995014023A1
(en)
*
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
US5912253A
(en)
|
1993-12-17 |
1999-06-15 |
Novartis Ag |
Rapamycin derivatives
|
|
US5362735A
(en)
|
1994-02-23 |
1994-11-08 |
Smithkline Beecham Corporation |
Rapamycin derivatives
|
|
US5639600A
(en)
|
1994-08-05 |
1997-06-17 |
The Regents Of The University Of California |
Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
|
|
JP3934705B2
(ja)
*
|
1995-05-26 |
2007-06-20 |
ノバルティス ファーマ株式会社 |
サイクロデキストリン組成物
|
|
KR19990022651A
(ko)
|
1995-06-07 |
1999-03-25 |
데이비드 엘. 버스테인 |
생물학적 사건에 대한 라파마이신 기재 조절방법
|
|
EP0833828B1
(en)
|
1995-06-09 |
2002-11-20 |
Novartis AG |
Rapamycin derivatives
|
|
US6258823B1
(en)
*
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
JP2002514165A
(ja)
*
|
1996-07-12 |
2002-05-14 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
病原性真菌感染の治療または予防材料および方法
|
|
US5922730A
(en)
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
|
CN1235608A
(zh)
|
1996-09-09 |
1999-11-17 |
美国家用产品公司 |
烷基化的雷帕霉素衍生物
|
|
US6342507B1
(en)
|
1997-09-05 |
2002-01-29 |
Isotechnika, Inc. |
Deuterated rapamycin compounds, method and uses thereof
|
|
US7087648B1
(en)
|
1997-10-27 |
2006-08-08 |
The Regents Of The University Of California |
Methods for modulating macrophage proliferation using polyamine analogs
|
|
CA2318402A1
(en)
*
|
1998-01-15 |
1999-07-22 |
Ariad Gene Therapeutics, Inc. |
Regulation of biological events using multimeric chimeric proteins
|
|
AU783158B2
(en)
*
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040001878A1
(en)
*
|
2002-06-26 |
2004-01-01 |
Deroyal Industries, Inc. |
Infused wound care dressings
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
CN1832939B
(zh)
|
2003-05-30 |
2010-04-28 |
杰明X医药品加拿大公司 |
用于治疗癌症或病毒病的三杂环化合物、组合物和方法
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
AU2004255340B2
(en)
*
|
2003-07-08 |
2008-05-01 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
SI2612862T1
(sl)
|
2004-05-13 |
2017-04-26 |
Icos Corporation |
Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
|
|
US20060189551A1
(en)
*
|
2004-10-04 |
2006-08-24 |
Duke University |
Combination therapies for fungal pathogens
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
US20060257337A1
(en)
|
2005-04-28 |
2006-11-16 |
David Sherris |
Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
|
|
EP1888550B1
(en)
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
CN101395155A
(zh)
|
2005-10-07 |
2009-03-25 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
|
CN103626742B
(zh)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
激酶的联-芳基间-嘧啶抑制剂
|
|
EP2385053B1
(en)
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20070203168A1
(en)
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
|
|
TW200815429A
(en)
|
2006-04-11 |
2008-04-01 |
Smithkline Beecham Corp |
Thiazolidinedione derivatives as PI3 kinase inhibitors
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
EP2074244A4
(en)
|
2006-07-28 |
2011-11-23 |
Pronomic Industry Ab |
CRYSTAL BREEDING METHOD AND REACTOR CONCEPT
|
|
DK2074122T5
(da)
|
2006-09-15 |
2014-03-17 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
WO2008070740A1
(en)
|
2006-12-07 |
2008-06-12 |
F.Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
WO2008110491A2
(en)
|
2007-03-09 |
2008-09-18 |
University Of Basel |
Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
|
|
HRP20151386T1
(hr)
|
2007-03-12 |
2016-02-26 |
Ym Biosciences Australia Pty Ltd |
Fenil aminopirimidinski spojevi i njihova primjena
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
US20090253733A1
(en)
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
|
AP2775A
(en)
|
2008-05-23 |
2013-09-30 |
Wyeth Llc |
Triazine compounds as P13 kinase and MTOR inhibitors
|
|
US8198441B2
(en)
|
2008-06-20 |
2012-06-12 |
Astrazeneca Ab |
Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
ES2345241B1
(es)
|
2009-03-16 |
2011-09-08 |
Lipopharma Therapeutics |
Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
|
|
SG174527A1
(en)
|
2009-03-27 |
2011-11-28 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
ES2500643T3
(es)
|
2009-04-03 |
2014-09-30 |
Verastem, Inc. |
Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas
|
|
WO2010118208A1
(en)
|
2009-04-09 |
2010-10-14 |
Exelixis, Inc. |
Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
|
|
WO2011130232A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
CN103108873A
(zh)
|
2010-07-16 |
2013-05-15 |
皮拉马尔企业有限公司 |
作为激酶抑制剂的取代的咪唑并喹啉衍生物
|
|
JO3003B1
(ar)
|
2011-01-14 |
2016-09-05 |
Lilly Co Eli |
مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
|
|
US8808256B2
(en)
|
2012-01-16 |
2014-08-19 |
Johnson & Johnson Vision Care, Inc. |
Eye drug delivery system
|
|
US9072678B2
(en)
|
2013-03-14 |
2015-07-07 |
Pathak Holdings Llc |
Methods for local drug delivery by microinjection
|
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
|
EP3102576B8
(en)
|
2014-02-03 |
2019-06-19 |
Vitae Pharmaceuticals, LLC |
Dihydropyrrolopyridine inhibitors of ror-gamma
|
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
|
US20160279108A1
(en)
|
2015-02-24 |
2016-09-29 |
University Of Kansas |
Targeted mtor inhibitors
|
|
US10683308B2
(en)
*
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
CA3061907A1
(en)
|
2017-05-02 |
2018-11-08 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
|
WO2020076738A2
(en)
|
2018-10-12 |
2020-04-16 |
Bellicum Pharmaceuticals, Inc |
Protein-binding compounds
|
|
MX2021007247A
(es)
|
2018-12-18 |
2021-07-15 |
Novartis Ag |
Derivados de rapamicina.
|
|
EP3914245A4
(en)
|
2019-01-22 |
2022-08-24 |
Aeovian Pharmaceuticals, Inc. |
MTORC-1 MODULATORS AND USES THEREOF
|
|
KR20210142689A
(ko)
|
2019-03-26 |
2021-11-25 |
노파르티스 아게 |
이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
|
|
KR20220128345A
(ko)
*
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
|
WO2021195599A1
(en)
|
2020-03-27 |
2021-09-30 |
Aeovian Pharmaceuticals, Inc. |
Mtorc1 modulators and uses thereof
|
|
EP4185590A2
(en)
|
2020-07-21 |
2023-05-31 |
Aeovian Pharmaceuticals, Inc. |
Mtorc1 modulators and uses thereof
|